Global Cancer Immunotherapy Vaccine Market Immuno oncology Clinical Trials Outlook 2025

“Global Cancer Immunotherapy Market & Clinical Trials Outlook 2025” report gives comprehensive insight on clinical and non-clinical developments in the field of cancer immunotherapy. According to report, cancer immunotherapy has emerged as the new growth frontier for the pharmaceutical companies involved in the clinical research and development of cancer drugs and therapeutics. Currently there are more than 2000 cancer immunotherapies based drugs/therapies are in clinical pipeline. Majority of these are in preclinical, Phase-I and Phase-II trials. There are 14 cancer vaccine, 44 Cancer monoclonal antibodies, 3 cancer cell therapies and 61 cancer Immunomodulators are commercially available in the market.

For Report Sample Contact: neeraj@kuickresearch.com

 

 

1. Immunotherapy: Mending Cancer Regimens

1.1 Preface to Cancer Immunotherapy

1.2 Evolution of Cancer Immunotherapy

 

2. Categorization of Cancer Immunotherapy

2.1 Specific Cancer Immunotherapy

2.1.1 Cancer Vaccines

2.1.2 Monoclonal Antibodies

2.2 Non-Specific Cancer Immunotherapy

2.2.1 Adoptive Cell Transfer Immunotherapy

2.2.2 Immune Checkpoint Inhibitors

 

3. Fundamentals of Cancer Vaccines

3.1 Prologue of Cancer Vaccines

3.2 Cancer Vaccines in Immunotherapy

3.3 Commercial Aspects of Cancer Vaccines

 

4. New Era of Monoclonal Antibodies

4.1 Rudiments of Monoclonal Antibodies

4.2 Advents of Monoclonal Antibodies

4.3 Commercial Aspects of Monoclonal Antibodies

 

5. Trails of T-Cell Therapies

5.1 Adoptive Cell Transfer Technology

5.2 Strategies of Adoptive Cell Transfer

5.3 Commercial Aspects of Adoptive Cell Therapy

 

6. Aspects of Immune Checkpoint Inhibitors

6.1 Prelude to Immune Checkpoint Inhibitors

6.2 Implications of Immunecheck Point Inhibitors

6.3 Commercial Aspects of Immune Checkpoint Inhibitors

 

 

7. Immunomodulators in Cancer Immunotherapy

7.1 Perspective of Immunomodulators

7.2 Clinical Aspects of Immunomodulators

7.3 Commercial Aspects of Immunomodulators

 

8. Oncolytic Viral Immunotherapy

8.1 Concept to Oncolytic Viruses

8.2 Potential Approaches of Oncolytic Viruses

8.3 Commercial Aspects of Oncolytic Viruses

 

9. Cytokines in Cancer Immunotherapy

9.1 Fundamentals of Cytokines

9.2 Classification of Cytokines

9.3 Commercial Aspects of Cytokines

 

10. Interferons in Immunotherapy

10.1 Potentials of Interferons

10.2 Classification of Interferons

10.3 Clinical Applications of Interferons

 

11. Interleukins in Immunotherapy

11.1 Potentials of Interleukins

11.2 Clinical Applications of Interleukins

 

12. GM-CSF in Immunotherapy

12.1 Potentials of GM-CSF

12.2 Clinical Applications of GM-CSF

 

13. Global Economic Evaluations

13.1 Economic Aspects of Cancer Immunotherapy

13.2 Cancer Immunotherapy Cost by Product

 

14. Market Aspects of Cancer Immunotherapy

14.1 Current Market Trends

14.2 Cancer Immunotherapy Pipeline Overview

 

 

15. Global Cancer Immunotherapy Market Dynamics

15.1 Favorable Market Parameters

15.2 Commercialization Challenges

 

16. Marketed Cancer Cell Therapies Drugs

16.1 Sipuleucel-T (Provenge®)

16.2 T-Lymphocyte Cell Therapy(Immuncell-LC®)

 

17. Marketed Cancer Cytokines Drugs

17.1 Aldesleukin (Proleukin®)

17.2 Denileukin Diftitox (ONTAK®)

17.3 Interferon Alpha (Multiferon®)

17.4 Interferon Alpha-2a (Roferon-A®)

17.5 Interferon Alpha-2a (Veldona®)

17.6 Interferon Alpha-2a Biosimilar(Inferon™/Inmutag™)

17.7 Interferon Alpha-2b(Intron® A)

17.8 Interferon Alpha-2b Biosimilar(Bioferon™)

17.9 Interferon Alpha-2b Biosimilar (Intalfa®)

17.10 Interferon Alpha-2b Biosimilar

17.11 Interferon-Alpha-n3 (Alferon N®)

17.12 Interferon-Beta-1b (Feron®)

17.13 Interferon-Gamma (Ogamma®)

17.14 Interleukin-2 Biosimilar (Ilcass)

17.15 Teceleukin (Imunace™)

 

18. Marketed Cancer Vaccines

18.1 Bladder Cancer Vaccine (PACIS®)

18.2 Bladder Cancer Vaccine

18.3 BV NSCLC 001

18.4 Dendritic Cell Vaccine (CreaVax-HCC®, CreaVax-PC® & CreaVax-RCC®)

18.5 Human Papillomavirus Vaccine Quadrivalent (Gardasil®/Silgard®)

18.6 Human Papillomavirus Vaccine Recombinant Bivalent (Cervarix®)

18.7 Melanoma Vaccine (MVax®)

18.8 Melanoma Vaccine (Melacine®)

18.9 Racotumomab (Vaxira®)

18.10 Sipuleucel-T (Provenge®)

18.11 Tertomotide (LucaVax)

18.12 Vitespen (Oncophage®)

 

19. Marketed Cancer Monoclonal Antibodies

19.1 Bevacizumab

19.2 Trastuzumab Emtansine

19.3 Trastuzumab Subcutaneous

19.4 Brentuximab Vedotin

19.5 Catumaxomab

19.6 Ipilimumab

19.7 Nivolumab

19.8 Pembrolizumab

19.9 Pertuzumab

19.10 Rituximab

19.11 Trastuzumab

 

20. Global Cancer Immunotherapy Market Future Prospects

 

21. Competitive Landscape

21.1 Abbvie

21.2 Advaxis

21.3 Altor BioScience

21.4 Amgen

21.5 Biogen Idec

21.6 Biogenomics

21.7 Celldex Therapeutics

21.8 Dendreon Corporation

21.9 Eli Lilly

21.10 Expression Genetics

21.11 Galena Biopharma

21.12 Genmab

21.13 Gilead Sciences

21.14 GlaxoSmithKline

21.15 ImmunoCellular Therapeutics

21.16 ImmunoGen

21.17 Inovio Pharmaceuticals

21.18 IRX Therapeutics

21.19 Merck

21.20 NeoStem Oncology

21.21 NewLink Genetics

21.22 Northwest Biotherapeutics

21.23 Novartis

21.24 Peregrine Pharmaceuticals

21.25 Pfizer

21.26 Philogen

21.27 Regulon

21.28 Roche

21.29 Seattle Genetics

21.30 ZymoGenetics